Check out the companies that make headlines before the alarm goes off:
Voice mark (ACN) – The consulting firm reported better-than-expected quarterly profit and revenue, but gave a weaker-than-expected current-quarter revenue forecast. Accenture points out the reduction in IT spending of corporate customers and the negative impact of a stronger dollar. However, Accenture gained 1% in pre-market trading.
Restaurants in Darden (DRI) – The parent company of Olive Garden and other restaurant chains fell 2.5% in the money market after reporting results for the quarter. Darden’s similar restaurant sales rose 4.2 percent, down from consensus FactSet estimates of 5.1 percent. Food and beverage costs also rose slightly more than expected.
KB Homepage (KBH), Lennar (LEN) – KB Home and Lennar both reported better-than-expected quarterly earnings, but homebuilders also posted lower-than-expected revenue as a downturn in the housing market weighed on orders. new home goods. KB Home is down 1.7% in pre-market trading, while Lennar is up 1%.
Sales force (CRM) – Salesforce shares jumped 1.9% in the money markets after the business software giant announced plans to operate more efficiently and increase profit margins. Salesforce is aiming for a 25% adjusted operating profit margin for fiscal 2026, compared with the 20% it has targeted for fiscal 2023.
Steelcase (SCS) – Steelcase reported better-than-expected profit for its most recent quarter, but the office furniture company’s revenue fell short of estimates. The company also cut its outlook for a slower-than-expected return to the office. Steelcase is down 1% in the pre-consumer market.
Novavax (NVAX) – The drugmaker’s stock fell 6.1% in pre-market trading after JP Morgan Securities downgraded it to “lightweight” from “neutral”. The company said its recent guidance cuts may not have gone far enough, due to falling vaccine demand as well as other factors.
HB is more complete (FUL) – HB Fuller jumped 2.2% in pre-market trading after a slight decline in earnings and revenue that missed estimates. The industrial adhesives maker reported an increase in market share and a lift in earnings at the end of its fiscal 2022.
Eli Lilly (LLY) – Eli Lilly rallied 1.4% in premarket trading after the FDA approved its cancer drug Retevmo for new use. Additionally, UBS upgraded the drugmaker’s stock to “buy” from “neutral” for a number of reasons, including reducing the risk surrounding weight loss drug Lilly tirzepatide.
FactSet Research (FDS) – The financial information services provider fell 7 cents from estimates with adjusted quarterly earnings of $3.13 per share. However, revenue beat Wall Street forecasts as FactSet reported an increase in organic revenue and subscription value year-over-year.